NEUROCRINE BIOSCIENCES INC Property, Plant and Equipment, Gross
NEUROCRINE BIOSCIENCES INC (NBIX) had Property, Plant and Equipment, Gross of $208.10 million as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-02-11
- 2025-12-31: Property, Plant and Equipment, Gross $208.10M.
- 2024-12-31: Property, Plant and Equipment, Gross $189.10M.
- 2023-12-31: Property, Plant and Equipment, Gross $153.80M.
- 2022-12-31: Property, Plant and Equipment, Gross $124.90M.
| Period end | Property, Plant and Equipment, Gross | Property, Plant and Equipment, Gross as first filed |
|---|---|---|
| 2025-12-31 | $208.10M 10-K · filed 2026-02-11 | |
| 2024-12-31 | $189.10M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $153.80M 10-K · filed 2025-02-10 | |
| 2022-12-31 | $124.90M 10-K · filed 2024-02-09 | |
| 2021-12-31 | $110.50M 10-K · filed 2023-02-09 | |
| 2020-12-31 | $86.30M 10-K · filed 2022-02-11 | |
| 2019-12-31 | $75.50M 10-K · filed 2021-02-05 | $75.47M 10-K · filed 2020-02-07 |
| 2018-12-31 | $62.14M 10-K · filed 2020-02-07 | |
| 2017-12-31 | $38.39M 10-K · filed 2019-02-08 | |
| 2016-12-31 | $32.22M 10-K · filed 2018-02-13 | |
| 2015-12-31 | $30.29M 10-K · filed 2017-02-14 | |
| 2014-12-31 | $31.25M 10-K · filed 2016-02-11 | |
| 2013-12-31 | $30.10M 10-K · filed 2015-02-09 | |
| 2012-12-31 | $36.22M 10-K · filed 2014-02-11 | |
| 2011-12-31 | $36.47M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |